Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01876953

Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

Phase I/II Study of the Combination of Dasatinib With Chemotherapy for High Risk Acute Myeloid Leukemia (AML) Patients

Sponsor: City of Hope Medical Center

Conditions Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia

Interventions cytarabine dasatinib idarubicin laboratory biomarker analysis

Updated 11 times since 2017 Last updated: Mar 28, 2022 Started: Sep 13, 2013 Primary completion: Apr 25, 2018 Completion: Apr 25, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to the budget issues, the study discontinued at Phase II.

Other terminated trials from City of Hope Medical Center

See all terminations from City of Hope Medical Center

Other Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trials with similar outcome

NCT00119366 · Phase PHASE2 · May 2019

Browse all Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trials

This PHASE1/PHASE2 trial investigates Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Del(5q) and is currently terminated or withdrawn. City of Hope Medical Center leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE1_PHASE2
Apr 2022 — Dec 2022 [monthly]

Terminated PHASE1_PHASE2

▶ Show 6 earlier versions

Oct 2021 — Apr 2022 [monthly]

Terminated PHASE1_PHASE2

Status: Completed → Terminated
Jan 2021 — Oct 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
May 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2
Feb 2017 — May 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

City of Hope Medical Center
National Cancer Institute (NCI)

Data source: City of Hope Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Duarte, United States